The number is a fourfold gain. In 100 men with early-stage hair loss, everyone used topical minoxidil for 12 weeks; the group that also rolled their scalp weekly grew four times the new hair per square centimetre, and 82% called their improvement substantial versus under 5% of the minoxidil-only group 1.
It held up when others ran it. A 68-man repeat saw the same pattern 2, deeper needles beat shallow ones 3, and pooling 22 trials, every adjunct study favoured needling 4. Even four men who'd stalled on minoxidil and finasteride regrew visible hair when it was added 5.
The base is narrow, though. The trials are small, mostly from a few clinics, and none run past six months. The direction is solid; the ceiling isn't pinned down.
Three numbers carry the whole protocol: depth, frequency, and the gap before the drug.
The clock runs on the hair cycle, so it lags.
- Weeks one to four: nothing visible. This is where most people quit.
- Weeks six to twelve: the shed slows; less hair in the drain, new fine hairs on close inspection 2.
- Three to six months: the part-line narrows, and January photos beat June ones 1.
- Beyond a year: the density holds only as long as you keep going.
The fine print — when to skip it, and what people get wrong
Why it fails: cosmetic 0.25 mm rollers never reach the follicle; monthly instead of weekly is below threshold; quitting at week eight; needling a dry scalp with no minoxidil in the picture; or a dirty roller giving you folliculitis.
Skip it with an active scalp infection or inflammation, on blood thinners, in pregnancy or breastfeeding (the minoxidil is the risk there, not the needle), or with a history of keloid scarring. Active alopecia areata: get a dermatologist's call first.
It doesn't work solo — the trials test it on top of minoxidil. Longer than 1.5 mm adds pain without adding hair. And it's not the skincare version: hair loss is a different depth, frequency, and evidence base from acne-scar needling.
- 1Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International Journal of Trichology. link
- 2Kumar MK, Inamadar AC, Palit A (2018). A randomized controlled, single-observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. Journal of Cutaneous and Aesthetic Surgery. link
- 3Faghihi G, Nakhaee MR, Asilian A, Iraji F, Nilforoushzadeh MA (2021). Microneedling in androgenetic alopecia; comparing two different depths of microneedles. Journal of Cosmetic Dermatology. link
- 4English RS, Ruiz S, DoAmaral P (2022). Microneedling and Its Use in Hair Loss Disorders: A Systematic Review. Dermatology and Therapy. link
- 5Dhurat R, Mathapati S (2015). Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian Journal of Dermatology. link
დაკავშირებული სახელმძღვანელოში (5)
- — Microneedling roughly quadruples what minoxidil does — it works by waking the follicle and letting the topical actually reach it.
- — Before the surgical option, microneedling plus minoxidil is the non-surgical route for earlier-stage thinning.
- — For hair, red light and scalp microneedling are both minoxidil boosters; pick one to add rather than chasing both.
- — Finasteride works from the inside; scalp microneedling is a do-it-yourself adjunct stacked on top of topical minoxidil.
- — The scalp version of microneedling targets hair follicles; the skin version targets scars and texture, with its own depth and cadence.
Scalp Microneedling
Reusable dermaroller $15–$40 one-time; dermapen $80–$200 plus $3–$10 cartridges. Self-administered. Minoxidil 5% adds ~$100–$200/year. Total well under $300/year for the home-protocol case the entry recommends. Clinic-administered or PRP-combined protocols cost much more but are not the default.
One ≈10-minute session weekly plus twice-daily minoxidil application. The microneedling session itself is minor; the burden lives in the daily topical that has to continue alongside it. Lifelong if the user wants to hold the gain.
Hair count gain visible by trichoscopy at 12 weeks and to the user/others by 24 weeks. Dhurat 2013 reported a 4× larger hair-count increase than minoxidil alone at 12 weeks (+91 vs +22 hairs/cm²); 82% of the microneedling arm reached ≥50% investigator-rated improvement vs 4.5% of controls. Visible part-line narrowing and reduced shed are the felt-experience markers.
Continued weekly-to-biweekly use sustains the density gain and slows the underlying AGA miniaturisation trajectory over years (Kumar 2018; English et al. 2022). Effect is maintenance-dependent — discontinuation returns the loss trajectory — but the cumulative aesthetic outcome is a meaningfully different aging hairline.
Multiple positive RCTs anchored by Dhurat 2013 (n=100), replicated by Kumar 2018 and Faghihi 2021; systematic review English et al. 2022 covers 22 hair-loss studies with consistent direction. Limitations: trials small (most n<100), single-centre, mostly run by a few Indian/Iranian groups, evaluator- but not patient-blinded, short follow-up. Mainstream dermatology guidelines have not yet incorporated it.
Indirect: AGA is associated with measurable distress, lowered self-esteem, and social-anxiety symptoms in affected men and women. Restoring visible density attenuates that — but the effect is downstream of the appearance change, not a direct biochemical mood action, hence trivial-positive rather than substantial.